Cryptococcal panniculitis in renal transplant recipient patient : a case report and review of the literature

Cryptococcus neoformans es un hongo dimorfo, oportunista, que afecta principalmente a pacientes inmunocomprometidos y que puede manifestarse en la piel mediante diversas presentaciones clínicas. Teniendo en cuenta el incremento del número de pacientes sometidos a trasplante, la inmunosupresión de estos y el riesgo de presentar este agente patógeno, se presenta el caso de un paciente con antecedente de trasplante renal, que presentó lesiones eritematosas en los miembros inferiores, de las cuales se tomó biopsia de piel y se confirmó el diagnostico de paniculitis por criptococo.Reporte de caso155-157Cryptococcus neoformas is a dimorphic opportunistic fungus that mainly affects immunocompromised patients and that can manifest in the skin through various clinical presentations. Given the increase in the number of patients undergoing transplantation, their immunosuppression and the risk of this pathogen, we present the case of a patient with a history of renal transplantation, who presented erythematous lesions in the lower limbs; a skin biopsy was performed confirming the diagnosis of cryptococcal panniculitis

De léntigo maligno a léntigo maligno melanoma

ResumenSe reporta un caso ilustrativo de un paciente de 77 años con lesión nodular pigmentada que apareció sobre una málula color café de 15 años de evolución. La biopcia reporta melanoma maligno CLARK IV, Breslow de 4 mm. Se revisa el riesgo de transformación de léntigo maligno a léntigo maligno melanoma.[González M, Peñaranda E, Acosta A, Rueda X, Rolón M. De léntigo maligno a léntigo maligno melanoma. MedUNAB 2002; 5(14):109-111].Palabras clave: Léntigo maligno, léntigo maligno melanoma, neoplasias de la piel.&nbsp

From lentigo maligna to lentigo maligna melanoma

Se reporta un caso ilustrativo de un paciente de 77 años con lesión nodular pigmentada que apareció sobre una mácula color café de 15 años de evolución. La biopsia reporta melanoma maligno Clark IV, Breslow de 4 mm. Se revisa el riesgo de transformación de léntigo maligno a léntigo maligno melanoma.[González M, Peñaranda E, Acosta A, Rueda X, Rolón M. De léntigo maligno a léntigo malignomelanoma. MEDUNAB 2002An illustrative case is reported of a 77-year-old patient with a pigmented nodular lesion that appeared on a 15-year-old brown macule. The biopsy reported malignant melanoma Clark IV, Breslow measuring 4 mm. The risk of transformation from lentigo maligna to lentigo maligna melanoma is reviewed.[González M, Peñaranda E, Acosta A, Rueda X, Rolón M. From lentigo maligna to lentigo malignamelanoma. MEDUNAB 200

Erratum to : Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

Introduction: There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients. Methods: Data were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe plaque psoriasis. Patients who self-identified as Hispanic were included in the Hispanic subgroup.Results: Efficacy responses (Psoriasis Area and Severity Index [PASI] 75/90/100 and Investigator's Global Assessment 2011 modified version 0/1) for secukinumab 300 mg were greater than for etanercept at week 12 in the Hispanic and non-Hispanic patient subgroups. At week 12 with secukinumab 300 mg, PASI 90/100 responses were achieved by 70.6%/35.9% of Hispanic patients and 58.0%/28.1% of non-Hispanic patients. At week 12 with secukinumab 150 mg, PASI 90/100 responses were achieved by 59.5%/25.1% of Hispanic patients and 41.2%/13.4% of non-Hispanic patients. In both subgroups, peak efficacy responses with secukinumab were observed at week 16 and were maintained to week 52.Conclusions: Secukinumab is highly effective for clearing psoriasis in both Hispanic and non-Hispanic patients.Funding: Novartis Pharmaceutical Corporation

Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis : Pooled Analysis of Four Phase 3 Trials

Altres ajuts: This study was funded by Novartis Pharmaceutical Corporation. Article processing charges and the fee for open access were funded by Novartis Pharmaceutical Corporation. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Technical assistance with editing and styling of the manuscript for submission was provided by Scott Forbes, Ph.D., of Oxford PharmaGenesis Inc. and was funded by Novartis Pharmaceuticals Corporation.There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients. Data were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe plaque psoriasis. Patients who self-identified as Hispanic were included in the Hispanic subgroup. Efficacy responses (Psoriasis Area and Severity Index [PASI] 75/90/100 and Investigator's Global Assessment 2011 modified version 0/1) for secukinumab 300 mg were greater than for etanercept at week 12 in the Hispanic and non-Hispanic patient subgroups. At week 12 with secukinumab 300 mg, PASI 90/100 responses were achieved by 70.6%/35.9% of Hispanic patients and 58.0%/28.1% of non-Hispanic patients. At week 12 with secukinumab 150 mg, PASI 90/100 responses were achieved by 59.5%/25.1% of Hispanic patients and 41.2%/13.4% of non-Hispanic patients. In both subgroups, peak efficacy responses with secukinumab were observed at week 16 and were maintained to week 52. Secukinumab is highly effective for clearing psoriasis in both Hispanic and non-Hispanic patients. Novartis Pharmaceutical Corporation. The online version of this article (doi:10.1007/s12325-017-0521-z) contains supplementary material, which is available to authorized users

Aplicación de los principios establecidos en la resolución 60/147 de la ONU en la JEP: ¿la reparación interna excluye la reparación integral?

Se pretende realizar el análisis de los medios de reparación integral en razón a la implementación en la justicia especial para la paz, con aceptación de las directrices enmarcadas en el ámbito internacional en el respeto y garantía de los derechos humanos, y su incidencia en las diferentes jurisdicciones internas, específicamente en la vinculatoriedad al ordenamiento jurídico colombiano de los principios establecidos en la resolución 60/147 de 2005 publicada por la Organización de las Naciones Unidas. Resaltando un arduo camino en las providencias emitidas por las Altas Cortes de un país que ha venido golpeado por un conflicto interno de más de medio siglo, en concreto desde un ámbito político y social de los diferentes escenarios impulsores o detractores del proceso de paz que se adelanta actualmente en Colombia y de los antecedentes del proceso de paz llevado con las Autodefensas unidas de Colombia, que manifiestan diversas especulaciones en medidas adoptadas por el Gobierno de turno en el anhelo de conseguir el derecho a la paz. Situación que establece un riesgo académico en la presente investigación al encaminarse en algunas de las posturas e ideologías plasmadas, al definir el cumplimiento de los ítems reguladores del sistema de verdad, justicia, reparación y garantía de no repetición, que sin término alguno generará sentimientos encontrados entre las diferentes formas de estudiar y concebir las vulneraciones notorias o aberrantes de los derechos fundamentales y del derecho internacional humanitario, en el acceso al resarcimiento de los perjuicios ocasionados al conglomerado social, y que por consiguiente solicita la aplicabilidad del principio de reparación integral.It is intended to carry out the analysis of the means of integral reparation due to the implementation in the special justice for peace, with acceptance of the guidelines framed in the international scope in the respect and guarantee of the human rights, and their incidence in the different internal jurisdictions, specifically in the linking to the Colombian legal system of the principles established in resolution 60/147 of 2005 published by the United Nations Organization. Highlighting an arduous journey in orders issued by the high courts of a country that has been hit by an internal conflict over half a century, particularly from a political and social environment of different drivers scenarios or detractors of the peace process that is currently advancing in Colombia and of the background to the peace process carried out with the United Self-Defense Forces of Colombia, which manifests various speculations on measures taken by the Government in turn in the desire to achieve the right to peace. Situation that establishes an academic risk in the present investigation as it is rooted in some of the postures and ideologies embodied, when defining the compliance of the items regulating the system of truth, justice, reparation and guarantee of non-repetition, which without any term will generate mixed feelings between the different ways of studying and conceiving notorious or aberrant violations of fundamental rights and international humanitarian law in access to compensation for the damages caused to the social conglomerate, and therefore calls for the applicability of the principle of integral reparation

Compromiso inflamatorio de las glándulas ecrinas de la piel en el síndrome de disfunción orgánica múltiple

The tissular injury triggers two types of inflammatory response: one is local and its purpose is the restablishment of the tissue well-being, the other one in which there is a widening or generalization of the inflammation, affect many organs. We present the case of a young man, mestecohybrid, farmer from the rural area of Mitú (Vaupés), who underwent a wasp sting in the right lego He received treatment with some drugs like analgesics, antihemetics and antibiotics, developing later fever, dyspnea, rash, cutaneous target lesions and multiorganic disfunction. The histopathology was in agreement with toxiderma brought on by medication. The patient received hemodynamic and ventilatory support, reaching full recovery

Competencia de los cuidadores informales de población en personas con enfermedad crónica en una institución prestadora de servicio, en san José de Cúcuta (Archivo Electrónico)

Ante la magnitud de la demanda y costos en la atención, las enfermedades crónicas han visibilizado en el ámbito domiciliario un creciente número de cuidadores, quienes se inician en el rol sin la capacitación y competencia requerida. Aspecto de actual significado desde lo académico e investigativo. Por ello es importante Identificar las competencias de los cuidadores de personas con enfermedad crónica en una Institución prestadora de servicio de San José de Cúcuta. Se reportaron niveles bajo y medio de competencia de los cuidadores en el ejercicio de su rol encontrándose en mayor afectación las categorías Conocimiento y Disfrutar (Bienestar). Es importante destacar que no se reportó cuidadores con un nivel de competencia Alto en el momento de desempeñar su rol.PregradoEnfermero(a

Relapsing polychondritis, an underestimated dermatological urgency: case report and literature review

Relapsing polychondritis is an autoimmune multisystemic disease with primary chondral involvement. Its high mortality and morbidity make it a real clinical challenge. A 32-year-old woman with a history of relapsing polychondritis, refractory to multiple treatments, with multisystem compromise, imminent risk of death due to severe tracheobronchial damage and difficult ventilatory support, and successful treatment with infliximab. Several treatments have been described in the literature, such as nonsteroidal anti-inflammatory drugs, corticosteroids, dapsone, azathioprine, cyclosporine, cyclophosphamide, and methotrexate. However, the cases refractory to conventional therapy may lead to chronicity, irreversibility, and death. As a result, a third-line therapy could improve the prognosis of these patients. Biological therapy is a good option for disease control and quality of life improvement. In addition, the physician should consider these treatments to avoid the chronicity and risk of death of these patients